Juurdepääsetavus ja lugemismugavus

Teksti suurus

Hele/tume režiim

Ridade vertikaalne vahekaugus

Kas teil on probleeme meie veebisaidi kasutamisega?
Kontakt

Pr Frank Holz

In Sellel leheküljel

Liikmete teave

Pr Frank Holz

Esindaja

Saksamaa

meeskond

Dr Philipp Herrmann

Saksamaa

CPMS ja digitaalmeditsiin (TWG10), geneetiline diagnostika (TWG6), teadusuuringud (TWG8), võrkkesta haruldased silmahaigused (WG1)
Vaata veel

HCP keskus

Silmahaiguste osakond hõlmab kõiki kirurgilisi oftalmoloogilisi operatsioone ning pakub hooldust kõigi kaasaegsete uuringute ja...

kontakt

University of Bonn, Germany

Ernst-Abbe-Strasse 2
53127 Bonn
Germany

Kliinilised uuringud

NCT05698316 Värbamine, aktiivne

A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Prediction of Disease Progression: (INTERCEPT-AMD)

Vaatlus
Vaadake kohtuprotsessi
voir la fiche

NCT01835002 Lõpetatud

This is a single-arm open label interventional safety trial with RP patients, who receive weekly TES for 6 months on 1 eye followed by observation for another 6 months without stimulation. The primary outcome measure is safety, indicated by the frequency and severity of adverse events.

Interventsiooniline
Vaadake kohtuprotsessi
voir la fiche
2018-001496-20 Värbamine, aktiivne

Clinical trials for A multi-national, multi-centre, double-masked, placebo-controlled proof of concept trial to evaluate the safety and efficacy of oral Soraprazan in Stargardt Phase 2, disease SMR-3438, Katairo

Interventsiooniline
Vaadake kohtuprotsessi
voir la fiche
NCT03584165 Värbamine, aktiivne

A Long-term Follow-up Study to Evaluate the Safety and efficacy of Retinal Gene Therapy in Subjects with choroideremia treated previously with Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) in an Antecedent Study.

Interventsiooniline
Vaadake kohtuprotsessi
voir la fiche
NCT02410122 Lõpetatud

The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy (ProgStar-4).

Vaatlus
Vaadake kohtuprotsessi
voir la fiche
NCT05811351 Värbamine, aktiivne

A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Interventsiooniline
Vaadake kohtuprotsessi
voir la fiche
NCT03364153 Aktiivne, ei värba

A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease

Interventsiooniline
Vaadake kohtuprotsessi
voir la fiche
NCT04435366 Lõpetatud

A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Interventsiooniline
Vaadake kohtuprotsessi
voir la fiche
NCT05384249 Värbamine, aktiivne

A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Non-infectious, Intermediate-, Posterior- or Pan-uveitis

Interventsiooniline
Vaadake kohtuprotsessi
voir la fiche
NCT03525600 Lõpetatud

A Phase 3, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal Pegcetacoplan Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Interventsiooniline
Vaadake kohtuprotsessi
voir la fiche
NCT04770545 Aktiivne, ei värba

A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Interventsiooniline
Vaadake kohtuprotsessi
voir la fiche
DRKS00023562 Värbamine, aktiivne

Evaluation of the effectiveness of transcorneal electrostimulation in patients with retinitis pigmentosa - a multicenter, prospective, randomized, controlled and double-blind study on behalf of the G-BA

Interventsiooniline
Vaadake kohtuprotsessi
voir la fiche